Transforming Communities through the Power of Meitheal Xentria's Approach

【商业合作︱生物技术公司Xentria与Meitheal Pharmaceuticals宣布就XTMAB-16达成在北美的独家许可协议】 2023年6月27日，临床阶段生物技术公司Xentria Inc.与Meitheal ... Xentria Inc./Meitheal. Pharmaceuticals Inc. In clinical trials. Molecule. Innovator product (company) Biosimilars. Company. Status. Omalizumab. Xolair® ( ... Xentria and Meitheal Pharmaceuticals announce exclusive licensing agreement for XTMAB-16 in North America ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... Tom Shea is the founding President of Xentria and the founding CEO of Meitheal Pharmaceutical, Inc. Xentria Inc a clinicalstage biotherapeutics company focused on developing therapeutics to address unmet clinical needs and Meitheal Pharmaceuticals Inc today ... 健友股份(603707)6月27日晚间公告，公司全资子公司香港健友（被许可方代表）及香港健友控股子公司Meitheal（被许可方）拟与Xentria签署许可协议，Xentria授予被许可方 ... Prior to joining Xentria and Meitheal, Tom was Vice President of Global Alliance Management for Sagent Pharmaceuticals and was responsible for global ... Targeted Delivery of ASO Gapmers to Muscle for the Treatment of Myotonic Dystrophy Type 1 · Xentria and Meitheal Collaborate on Breakthrough Lung ...